Core Viewpoint - Abacus Global Management, Inc. is facing significant scrutiny and a decline in share price due to allegations of improper accounting practices, as detailed in two critical reports from Morpheus Research within a week [1][3][5]. Group 1: Allegations and Reports - Morpheus Research published an initial report on June 4, 2025, alleging that Abacus engaged in an "accounting scheme" by using "mark-to-model" accounting and underestimating life expectancies, leading to the creation of "fake revenue" [3][4]. - The second report from Morpheus, released on June 12, 2025, escalated the allegations by presenting new evidence of undisclosed related-party dealings and questioning the independence of the actuarial firm Lewis & Ellis, which Abacus claimed had vetted its asset valuations [5][6]. Group 2: Market Reaction - Following the initial Morpheus report, Abacus's shares experienced a decline of over 20% in a single trading day [4]. - The ongoing investigations and negative reports have led to a continued sharp decline in Abacus's share price, raising concerns among investors [6]. Group 3: Company Response - In response to the allegations, Abacus published a rebuttal on June 10, 2025, asserting that it had retained Lewis & Ellis to validate its balance sheet, claiming the firm has a "sterling reputation" [4]. - However, Morpheus's follow-up report indicated that Abacus's rebuttal was inadequate and contradicted its own SEC filings, further intensifying scrutiny on the company's financial practices [5].

Abacus Global Management (ABL) 2025 Investor Day June 12, 2025 09:30 AM ET Speaker0 To our presentation today. And at Abacus, Abacus is continuing to grow and expand and take a look at a business model that started in one area related to life insurance policies and sourcing those and educating people around the value of their life insurance policies to asset management to potentially private wealth management and then capitalizing on all the lifespan data and technology that we've been able to do and instit ...

Core Viewpoint - The Schall Law Firm is investigating Abacus Global Management, Inc. for potential violations of securities laws, particularly concerning misleading statements and undisclosed information [1][2]. Group 1: Investigation Details - The investigation centers on whether Abacus issued false or misleading statements and failed to disclose critical information to investors [2]. - A report by Morpheus Research claims that Abacus changed its portfolio valuation methodology to present a more favorable financial picture, suggesting that the company is involved in an accounting scheme related to life settlements [2]. Group 2: Company Background - Abacus Global Management is identified as a SPAC (Special Purpose Acquisition Company) with a valuation of $794 million [2]. - The report also raises concerns about the methodologies used by Abacus to estimate life expectancy, indicating potential irregularities in their calculations [2]. Group 3: Legal Representation - The Schall Law Firm is reaching out to shareholders who may have suffered losses and is offering free consultations regarding their rights [3].

Core Viewpoint - Abacus Global Management strongly refutes the allegations made in a short seller's report, asserting that the claims regarding its reliance on a single life expectancy provider and inflated balance sheet valuation are incorrect [2][22]. Group 1: Response to Short Seller Allegations - The short seller's report claims that Abacus relies too heavily on Lapetus Solutions for life expectancy estimates, which the company denies, stating that it does not depend on Lapetus for portfolio valuation [2][6]. - Abacus engaged Lewis and Ellis, a third-party actuarial firm, to validate its policy balance sheet, confirming that the valuation of $449 million as of March 31, 2025, aligns closely with its own reported valuation of $446 million [9][6]. - The company emphasizes that its valuation methodology incorporates a mark-to-market approach, which is based on actual market transactions rather than solely on life expectancy estimates [12][10]. Group 2: Valuation Methodology - Abacus employs a dual valuation approach: life expectancy estimates for consumer-facing transactions and market-based valuations for balance sheet management, ensuring fair pricing and accurate asset valuation [10][11]. - The company prioritizes market reality in its trading portfolio, which allows for a more accurate reflection of asset value based on actual transaction history [20][12]. - Recent market transactions support the accuracy of Abacus's valuation model, with the company selling 226 policies for $141.4 million, closely matching the estimated balance sheet value of $139.1 million [15][16]. Group 3: Shareholder Commitment and Future Outlook - Abacus executives and shareholders collectively own approximately 46% of the outstanding shares, with a two-year lock-up period expiring on July 3, 2025, which is expected to positively impact the company's inclusion in the Russell 2000 and 3000 indices [17][19]. - The company asserts that the expiration of the lock-up period is not an opportunity for large shareholders to cash out but rather a chance to drive the company towards its next milestones [18][19]. - Abacus is committed to transparent communication with shareholders regarding any future share sales, emphasizing its long-term dedication to increasing shareholder value [20][21].

Core Viewpoint - Abacus Global Management has authorized a $20 million share repurchase program, reflecting confidence in its business model and balance sheet amidst a short attack on its stock price [1][2]. Group 1: Share Repurchase Program - The share repurchase program is effective from June 5, 2025, and will last for up to 18 months [1]. - The company may repurchase shares through various methods, including open market transactions and block trades, at its discretion based on several factors [2]. - The program is expected to be funded using cash on hand and anticipated future free cash flow [2]. Group 2: Management's Response - The CEO of Abacus stated that the current depressed share price presents a buying opportunity, supported by the new share repurchase program and employee investments totaling over $2 million [2]. - The company is committed to pursuing legal action against those responsible for the short attack [3]. Group 3: Company Overview - Abacus Global Management specializes in alternative asset management, data-driven wealth solutions, and technology innovations, focusing on longevity-based assets and personalized financial planning [8].

Company Overview - Abacus Global Management, Inc. operates as an alternative asset manager and market maker [3] Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Abacus Global, focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1] - The investigation follows a report published by Morpheus Research, which accused Abacus Global of engaging in an accounting scheme related to life settlements, leading to a significant drop in stock price [3] Market Reaction - Following the publication of the Morpheus Research report, Abacus Global's stock price fell by more than 21% [3]

ATLANTA, June 04, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL) complied with federal securities laws. On June 4, 2025, Morpheus Research published a report alleging that Abacus’s returns “are primarily manufactured by the systematic overvaluation of its assets through an opaque ‘mark to model’ accounting scheme that closely mirrors past blow-ups in the life settlements industry.” Following this report, the pri ...

ORLANDO, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leader in the alternative asset management space, today provided the following response to a false and misleading short attack. Abacus has been buying and selling life insurance policies for over two decades with long-standing and trusted counter-party relationships. If Abacus used flawed data causing over-valuation of the underlying insurance product assets, the Company would be goin ...

BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Abacus Global Management, Inc. (Nasdaq: ABL) for potential securities law violations. Investors who have lost money in their Abacus Global Management, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/abl. What is this all about? Shares of Abacus fell over 15% in intraday trading on June 4, 2025, after Morpheus Research published a r ...

Core Viewpoint - Abacus Life, Inc. (ABL) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For the fiscal year ending December 2025, Abacus Life, Inc. is projected to earn $0.76 per share, reflecting a 15.2% increase from the previous year, with a 2% rise in the Zacks Consensus Estimate over the past three months [8]. Zacks Rating System - The Zacks Rank stock-rating system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The upgrade of Abacus Life, Inc. to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].